WO2002016574A3 - Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type - Google Patents

Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type Download PDF

Info

Publication number
WO2002016574A3
WO2002016574A3 PCT/EP2001/009102 EP0109102W WO0216574A3 WO 2002016574 A3 WO2002016574 A3 WO 2002016574A3 EP 0109102 W EP0109102 W EP 0109102W WO 0216574 A3 WO0216574 A3 WO 0216574A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
specifically cleaved
type
peptide sequences
identifying peptides
Prior art date
Application number
PCT/EP2001/009102
Other languages
German (de)
French (fr)
Other versions
WO2002016574A2 (en
Inventor
Ralph Reimholz
Frank Ploeger
Original Assignee
Phylos Inc
Ralph Reimholz
Frank Ploeger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phylos Inc, Ralph Reimholz, Frank Ploeger filed Critical Phylos Inc
Priority to CA002420065A priority Critical patent/CA2420065A1/en
Priority to EP01962911A priority patent/EP1314039A2/en
Priority to JP2002522247A priority patent/JP2004507240A/en
Priority to AU2001283985A priority patent/AU2001283985A1/en
Publication of WO2002016574A2 publication Critical patent/WO2002016574A2/en
Publication of WO2002016574A3 publication Critical patent/WO2002016574A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

The invention relates to methods for detecting and identifying peptides that can be specifically cleaved, using a defined amino acid sequence based on a library of nucleic acid peptide fusion molecules. According to said methods, the variable part of the peptides is coded by the respective nucleic acid fused thereto, using proteolytically active solutions. The invention also relates to the use of said peptides for diagnosis.
PCT/EP2001/009102 2000-08-22 2001-08-07 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type WO2002016574A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002420065A CA2420065A1 (en) 2000-08-22 2001-08-07 Methods for indentifying specifically cleavable peptides and use of such peptide sequences
EP01962911A EP1314039A2 (en) 2000-08-22 2001-08-07 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type
JP2002522247A JP2004507240A (en) 2000-08-22 2001-08-07 Methods for identifying specific cleavable peptides and uses of such peptide sequences
AU2001283985A AU2001283985A1 (en) 2000-08-22 2001-08-07 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10041238A DE10041238A1 (en) 2000-08-22 2000-08-22 Process for the identification of specifically cleavable peptides and use of such peptide sequences
DE10041238.6 2000-08-22

Publications (2)

Publication Number Publication Date
WO2002016574A2 WO2002016574A2 (en) 2002-02-28
WO2002016574A3 true WO2002016574A3 (en) 2002-09-06

Family

ID=7653429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009102 WO2002016574A2 (en) 2000-08-22 2001-08-07 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type

Country Status (6)

Country Link
EP (1) EP1314039A2 (en)
JP (1) JP2004507240A (en)
AU (1) AU2001283985A1 (en)
CA (1) CA2420065A1 (en)
DE (1) DE10041238A1 (en)
WO (1) WO2002016574A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013623A1 (en) * 1992-12-11 1994-06-23 Chiron Corporation Synthesis of encoded polymers
US5563041A (en) * 1993-12-30 1996-10-08 Behringwerke Aktiengesellschaft Method for determining platelet aggregation
WO1997047314A1 (en) * 1996-06-10 1997-12-18 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
US5981200A (en) * 1996-01-31 1999-11-09 The Regents Of The University Of California Tandem fluorescent protein constructs
EP0962527A1 (en) * 1996-10-17 1999-12-08 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
JP2001103966A (en) * 1999-10-06 2001-04-17 Nof Corp Hybrid cell, monoclonal antibody, production method and assay
WO2001075088A1 (en) * 2000-04-05 2001-10-11 Esbatech Ag Method for identify polypeptides with protease activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ATE332368T1 (en) * 1997-01-21 2006-07-15 Gen Hospital Corp SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013623A1 (en) * 1992-12-11 1994-06-23 Chiron Corporation Synthesis of encoded polymers
US5563041A (en) * 1993-12-30 1996-10-08 Behringwerke Aktiengesellschaft Method for determining platelet aggregation
US5981200A (en) * 1996-01-31 1999-11-09 The Regents Of The University Of California Tandem fluorescent protein constructs
WO1997047314A1 (en) * 1996-06-10 1997-12-18 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
EP0962527A1 (en) * 1996-10-17 1999-12-08 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
JP2001103966A (en) * 1999-10-06 2001-04-17 Nof Corp Hybrid cell, monoclonal antibody, production method and assay
WO2001075088A1 (en) * 2000-04-05 2001-10-11 Esbatech Ag Method for identify polypeptides with protease activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'AMICO A V ET AL: "THROMBIN IMPLICATIONS FOR INTRATUMOR THERAPY AGAINST METASTASIS", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 114, no. 2, 1988, pages 129 - 132, XP002187158, ISSN: 0171-5216 *
GOODMAN AND GILMAN: "Pharmacological basis of therapeutics", 1991, MCGRAW-HILL INTERNATIONAL EDITIONS, SINGAPORE, XP002187262, 2 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 21 3 August 2001 (2001-08-03) *

Also Published As

Publication number Publication date
JP2004507240A (en) 2004-03-11
EP1314039A2 (en) 2003-05-28
WO2002016574A2 (en) 2002-02-28
AU2001283985A1 (en) 2002-03-04
DE10041238A1 (en) 2002-03-07
CA2420065A1 (en) 2003-02-19

Similar Documents

Publication Publication Date Title
WO1999057311A3 (en) Novel method for the identification of clones conferring a desired biological property from an expression library
WO2001057194A3 (en) Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
WO2003052054A3 (en) Bgl5 beta-glucosidase and nucleic acids encoding the same
WO2003027306A3 (en) Bgl3 beta-glucosidase and nucleic acids encoding the same
WO2004101759A3 (en) Novel lipolytic enzyme lip2
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
WO2003052055A3 (en) Egvii endoglucanase and nucleic acids encoding the same
WO2003052056A3 (en) Egviii endoglucanase and nucleic acids encoding the same
WO2001052789A3 (en) PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF
WO1999006587A3 (en) Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
WO2004043980A3 (en) Bgl6 beta-glucosidase and nucleic acids encoding the same
WO2004048592A3 (en) Bgl7 beta-glucosidase and nucleic acids encoding the same
WO2003052118A3 (en) Bgl4 beta-glucosidase and nucleic acids encoding the same
WO2002016418A3 (en) An iap binding peptide or polypeptide and methods of using the same
WO2001032684A3 (en) Method for linking molecular substances based on the affinity of the proline-rich amino acid sequences and protein domains of type ww
WO2002018443A3 (en) A recombinant monoclonal antibody to phosphotyrosine-containing proteins
NZ527971A (en) Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2000050607A3 (en) Goodpasture antigen binding protein
WO2002077241A3 (en) Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2005051975A3 (en) Methods for obtaining molecules with reduced immunogenicity
WO2002016574A3 (en) Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type
EP1182253A3 (en) Method for improving the thermostability of proteins
WO2003002730A3 (en) Method for detecting calpain 3 activity in a biological sample and peptides for implementing said method
WO2003057709A3 (en) Method and reagent for the detection of proteins and peptides
WO2004035733A3 (en) Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001962911

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001283985

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2420065

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002522247

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001962911

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001962911

Country of ref document: EP